- Home
- Publications
- Publication Search
- Publication Details
Title
CD72 is a pan‐tumor antigen associated to pediatric acute leukemia
Authors
Keywords
-
Journal
CYTOMETRY PART A
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-25
DOI
10.1002/cyto.a.24790
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- (2022) Joseph D. Khoury et al. LEUKEMIA
- Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A/MLL1-rearranged B-ALL
- (2021) Matthew A Nix et al. Cancer Discovery
- Strong expansion of normal CD19‐negative B‐cell precursors after the use of blinatumomab in the first‐line therapy of acute lymphoblastic leukaemia in children
- (2021) Ekaterina Mikhailova et al. BRITISH JOURNAL OF HAEMATOLOGY
- Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer
- (2021) Andrew DJ. Pearson et al. EUROPEAN JOURNAL OF CANCER
- An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report
- (2021) Margarita Maurer-Granofszky et al. Cancers
- Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer
- (2018) John K. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000
- (2016) Prashant R. Tembhare et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases
- (2016) Kiran Ghodke et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- CREB engages C/EBPδ to initiate leukemogenesis
- (2016) C Tregnago et al. LEUKEMIA
- NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group
- (2016) V Bisio et al. LEUKEMIA
- Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia
- (2015) L. Karawajew et al. HAEMATOLOGICA
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia
- (2015) L. Karawajew et al. HAEMATOLOGICA
- A Mass Spectrometric-Derived Cell Surface Protein Atlas
- (2015) Damaris Bausch-Fluck et al. PLoS One
- Interaction of CD5 and CD72 is involved in regulatory T and B cell homeostasis
- (2014) Mingke Zheng et al. IMMUNOLOGICAL INVESTIGATIONS
- Screening of novel genetic aberrations in pediatric acute myeloid leukemia: a report from the AIEOP AML-2002 study group
- (2012) M. Pigazzi et al. BLOOD
- MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study
- (2011) M Pigazzi et al. LEUKEMIA
- Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible
- (2008) Michael Norbert Dworzak et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation